Mochida Launches Teriparatide Biosimilar for the Treatment of Osteoporosis in Japan

 Mochida Launches Teriparatide Biosimilar for the Treatment of Osteoporosis in Japan

Mochida Launches Teriparatide Biosimilar for the Treatment of Osteoporosis in Japan

Shots:

  • Mochida launched “Teriparatide BS subcutaneous injection Kit 600μg MOCHIDA” as it has been listed on the NIH reimbursement price list
  • The launch will improve QoL and lead to the reduction of the financial burden of patients with osteoporosis. The teriparatide biosimilar has developed in collaboration with Gedeon Richter
  • Teriparatide BS Injection Kit 600μg is a novel biosimilar approved in Japan targeted for osteoporosis with a recommended dose of 20 μg SC once a day that enhances bone formation and improves bone structure. It is a disposable kit preparation with the delivery device and available for self-injection

Click here to­ read full press release/ article | Ref: Mochida | Image: Mochida

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post